Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
about
Ivabradine as adjuvant treatment for chronic heart failureIvabradine as adjuvant treatment for chronic heart failureRecent advances in treatment of heart failureThe Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic PotentialAdvances in the management of heart failure: the role of ivabradineHeart rate and use of beta-blockers in stable outpatients with coronary artery diseaseResting heart rate and risk of metabolic syndrome in adults: a dose-response meta-analysis of observational studies.Genetic loci associated with heart rate variability and their effects on cardiac disease risk.Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study.Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.Almanac 2011: Heart Failure. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.Pacemaker current inhibition in experimental human cardiac sympathetic activation: a double-blind, randomized, crossover study.Risk-benefit assessment of ivabradine in the treatment of chronic heart failureClinical presentation and management of stable coronary artery disease in Austria.Resting heart rate as predictor for left ventricular dysfunction and heart failure: MESA (Multi-Ethnic Study of Atherosclerosis).The in vivo regulation of heart rate in the murine sinoatrial node by stimulatory and inhibitory heterotrimeric G proteins.[Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry].Circulating plasma serine208-phosphorylated troponin T levels are indicator of cardiac dysfunction.Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitusIvabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practiceThe association between resting heart rate, cardiovascular disease and mortality: evidence from 112,680 men and women in 12 cohorts.New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association.Prognostic value of admission heart rate in patients with ST-segment elevation myocardial infarction: role of type 2 diabetes mellitus.Variation in resting heart rate over 4 years and the risks of myocardial infarction and death among older adultsAssociation between resting heart rate across the life course and all-cause mortality: longitudinal findings from the Medical Research Council (MRC) National Survey of Health and Development (NSHD).The causes, consequences, and treatment of left or right heart failureTransmural heterogeneity and remodeling of ventricular excitation-contraction coupling in human heart failure.Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial.Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart StudyResting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysisCardiovascular remodelling in coronary artery disease and heart failure.Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot TrialRegulation of β-adrenergic control of heart rate by GTP-cyclohydrolase 1 (GCH1) and tetrahydrobiopterin.The "funny" current (I(f)) inhibition by ivabradine at membrane potentials encompassing spontaneous depolarization in pacemaker cells.The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome PatientsOverdrive ventricular pacing in pacemaker recipients with permanent atrial fibrillation and sleep apnea.Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression.Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review.Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate.
P2860
Q24185982-554B2904-4FD1-410B-977A-0746B8AB308AQ24201614-CB54D5CF-267E-47F7-9BBC-101FB3E9F092Q26766223-18C1FF34-5538-40B8-B76C-81171DA08346Q26781422-59F6B4AA-97DA-4ACB-9D27-640431202452Q28072418-1E5DC38C-52B9-4BD9-BE57-E8B2102EE9F7Q28730142-5E20B4B9-CE3E-4123-911D-D858237C1330Q30240703-0DA3E1B5-3A01-4B08-A551-9296FEC1E07AQ30313100-1E0B6781-B9F0-4D51-AB63-AD887FF9DE55Q30318221-B765F1BD-01CB-48F4-AC88-5EF360283983Q30318280-EDDC0F5C-15BE-4909-B0AF-F1119B492C5DQ30451215-5A247551-52C4-4C21-B699-3EEC9C05F922Q30608315-2C1FA750-E57A-4BF3-92EE-ACD7FEC42C3CQ33163797-4734F07E-095E-47B7-9DC6-F69AB3F2EE0FQ33568592-5BFE6094-2E31-4C88-B87C-E8FA2655CD9BQ33610452-AF66FA64-A10C-4F04-A101-3B387EBD6964Q33682532-F06C1BA6-69E9-4BBA-B876-E50386369AB0Q33816888-50505334-1401-4DD6-8D87-CA7C8E18E286Q33912546-64F7FA3D-A1A4-4F87-B291-12A069B61074Q34154800-CD62BE03-F517-4DE8-882C-7242735763A3Q34222683-1024D606-F165-4A90-9E26-208681925554Q34253493-6829EE02-2611-47E8-8A87-88341758B3B7Q34283066-C4CF8930-5BE5-4247-B302-CF6B13CD0664Q34387086-A124F681-E87A-467E-A2E7-31514E0754DDQ34478486-97743CD6-9403-41CE-AE43-AEDD0C496E33Q34860874-12195397-1F25-4F39-B457-A0026D62DE3FQ34938629-4033E915-5FEE-4DAE-A856-BDCE0D1A4C75Q34987168-F4437213-D043-4C56-A8B8-0DEDD0743AC5Q34999647-D3DE935E-AD2D-4B89-AADF-9D959AEDABFEQ35006600-DBDC06C8-E486-43C6-94C6-FE49F6927D70Q35021769-55C250C7-0760-456B-9AD4-482C83F5CFD7Q35088114-F312770F-955C-444A-8BA8-1A766605546DQ35090566-1E35AB77-4510-4326-9EF2-DACE0C6CA61DQ35779867-BF9AF0FC-6E58-4269-ADAA-0F8C781A4EE8Q35792741-FBD8148C-1826-4504-B105-93FBFFFAF1B0Q35913417-5D147ADB-B3EC-4650-A905-003E8A36DBF0Q35914816-A58AA639-BF7D-4E43-BD6B-62C726421EBFQ36001004-2F251650-5B84-4EA1-8080-B0F89927A28DQ36024921-F2EE9EA5-88B7-40D1-AD62-F579166FC0B2Q36041575-10A31041-301E-4201-B15B-F06DC106DAF2Q36059223-FF76B664-2BF5-4FD2-A487-3A332286FCDC
P2860
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Heart rate as a risk factor in ...... ised placebo-controlled trial.
@en
Heart rate as a risk factor in chronic heart failure
@nl
type
label
Heart rate as a risk factor in ...... ised placebo-controlled trial.
@en
Heart rate as a risk factor in chronic heart failure
@nl
prefLabel
Heart rate as a risk factor in ...... ised placebo-controlled trial.
@en
Heart rate as a risk factor in chronic heart failure
@nl
P2093
P50
P1433
P1476
Heart rate as a risk factor in ...... ised placebo-controlled trial.
@en
P2093
Ariane Dubost-Brama
Guy Lerebours
Jeffrey S Borer
Michael Böhm
SHIFT Investigators
P304
P356
10.1016/S0140-6736(10)61259-7
P407
P577
2010-09-01T00:00:00Z